Drug Costs Not A Primary Driver Of Rare Disease Economic Burden
Executive Summary
EveryLife Foundation study finds inpatient and outpatient care, not prescription drugs, are the primary excess medical costs associated with rare diseases.
You may also be interested in...
6,000, 7,000, 10,000? Why Counting Rare Diseases Is So Difficult
FDA, NIH, sponsors and others use different figures, but some want everyone will settle on 10,000 for policy discussions, advocacy and research.
ICD Code Breaking: Rare Disease Advocates Want Simpler, Shorter Nomination Process
A group would look at the diseases that need codes and which to add initially, then consider updates to the code nomination process, in an effort to lower costs for rare disease patients.
Orphan Drug Spending: Could Sequence Of Indications Offer Pricing Policy Solution?
Focusing on orphan-first drugs may be best route to address pricing concerns, Health Affairs study suggests after finding that just one-fifth of spending on 15 top-selling partial orphan drugs was for the drugs’ rare disease indications.